Case Study: Developing Health Systems Resources
Middle East Program in Health Economics and Health Technology Assessment, Bristol-Myers Squibb
A 3-module program on Health Economics and Outcomes Research (HEOR) was developed by the University of Washington Department of Pharmacy, with the support of a grant from Bristol-Myers Squibb's Middle East/Africa division. The program is designed to educate decision makers from various countries in the Middle East on the foundational principles of Health Economics and Outcomes Research, in order to critically conduct health economic evaluations of pharmaceuticals and assess health technologies through a Health Technology Assessment. The program allows participants to gain an understanding of decision modeling, patient-reported outcomes, micro-simulation and assessment of uncertainty and principles and practice of Health Technology Assessment (HTA).
Based on experience, the program coordinators decided that the program could be enhanced by providing a pre-assessment of the attendees knowledge to understand their level of expertise and pre-work material to not only set the stage but also begin engaging attendees from the start of the program. These lessons will be applied to future programs.
Results to Date?
Qualitative: Participants were given a strong foundation of HEOR knowledge in a robust framework. Their understanding of the material was reinforced by their engagement in the course. Participants expressed how the knowledge gained from the program will impact their daily practice and clarified the challenges in decision making by adopting new methods and the role of a health economics department.
Quantitative: More than 25 representatives from 3 gulf countries (United Arab Emirates, Kuwait and Bahrain) have received training.
Related Case Studies on Developing Health Systems Resources
- Educating Healthcare Workers in Saudi Arabia, Roche
- Strengthening Diagnostics in Africa, Roche
- Changing Diabetes in Pregnancy, Novo Nordisk
- e-Learning to Reduce Maternal and Child Mortality, Novartis
- ColaLife, Johnson & Johnson
- Strengthening Healthcare Systems: 20 Percent Reinvestment Initiative, GSK
- Middle East Program in Health Economics and Health Technology Assessment, Bristol-Myers Squibb
- Changing Diabetes in Children, Novo Nordisk
- Transnet-Phelophepa Healthcare Train, Roche
- Alliance to Reduce Disparities in Diabetes, Merck
- Melanoma Exposed™. Screen. Protect. Know. Tell., Bristol-Myers Squibb
- Strengthening Healthcare Systems Through Investment in Community Health Workers, GlaxoSmithKline
- Takeda Initiative, Takeda Pharmaceutical Company Limited
- Jian Kang Kuai Che (“Health Express”), Novartis International AG